Swedish Genovis AB recently announced the signing of a new agreement with a major pharmaceutical company.
Genovis has not revealed the name of the new business partner but announces that the one-year development project agreement is worth approximately 100 000 US dollars. The project will adapt their products from the protein characterization portfolio to the customer’s technology platform.
“We look forward to launching this initiative together with our customer. This project demonstrates the interest in Genovis’ unique products and is a recognition of our skills and experience in characterizing antibody-based drugs,” says Sarah Fredriksson, CEO of Genovis, in a press release.
The Lund-based company develops and sells enzymes (protein engineering portfolio) in product formats that facilitate development and quality control of and biological drugs.